Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.5177
-0.0150-2.82%
Pre-market: 0.52390.0062+1.20%05:45 EDT
Volume:5.75M
Turnover:3.01M
Market Cap:143.92M
PE:-1.04
High:0.5480
Open:0.5400
Low:0.5104
Close:0.5327
52wk High:2.55
52wk Low:0.5104
Shares:278.00M
Float Shares:245.00M
Volume Ratio:1.65
T/O Rate:2.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:4.60
PE(LYR):-2.01

Loading ...

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

THOMSON REUTERS
·
Jun 11

Humacyte - to Use Net Proceeds for Symvess Commercialization and Pipeline Development

THOMSON REUTERS
·
Jun 11

Humacyte ATEV beats AV fistula on catheter-free days in interim Phase 3 V012 trial in female dialysis patients

Reuters
·
Jun 11

Humacyte Atev Met Superiority Primary Endpoint Compared to Standard of Care Av Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

THOMSON REUTERS
·
Jun 11

Humacyte - Study Enrollment to Terminate After Meeting Primary Endpoint

THOMSON REUTERS
·
Jun 11

Humacyte - to File Supplemental Bla With FDA in Second Half of 2026

THOMSON REUTERS
·
Jun 11

Humacyte shareholders approve increase in authorized common shares to 550 million

Reuters
·
Jun 10

Humacyte Price Target Maintained With a $2.00/Share by BTIG

Dow Jones
·
Jun 08

Humacyte Is Maintained at Speculative Buy by Benchmark

Dow Jones
·
Jun 01

Humacyte price target raised to $2 from $1 at Benchmark

TIPRANKS
·
Jun 01

Humacyte Price Target Maintained With a $3.00/Share by HC Wainwright & Co.

Dow Jones
·
May 27

Humacyte announces presentation at VASA meeting on self-repair ATEV

TIPRANKS
·
May 26

Humacyte says interim Phase 3 dialysis access study results due June 11

Reuters
·
May 26

Humacyte director Kathleen Sebelius acquires 56,818 shares for $49,999.84

Reuters
·
May 21

Humacyte director Michael T. Constantino acquires common shares worth $9,840

Reuters
·
May 21

Humacyte Announces Symvess® Is NOW Under Contract With the Strategic Acquisition Center (Sac) of the U.S. Department of Veterans Affairs

THOMSON REUTERS
·
May 20

Press Release: Humacyte Announces Symvess(R) is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

Dow Jones
·
May 20

Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements

Simply Wall St.
·
May 16

Humacyte Is Maintained at Buy by BTIG

Dow Jones
·
May 14

Humacyte Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13